Why is Nektar Therapeutics facing a securities class action lawsuit?

Investors allege Nektar made misleading statements about the REZOLVE-AA clinical trial, particularly regarding enrollment practices and compliance with trial protocols.

What is the REZOLVE-AA trial mentioned in the Nektar lawsuit?

REZOLVE-AA is a clinical study evaluating a treatment for alopecia areata. The lawsuit focuses on whether the trial was conducted according to proper enrollment instructions and protocol standards.

What problems are alleged with enrollment in Nektar’s REZOLVE-AA trial?

Investors claim participants may have been enrolled in ways that did not fully follow trial protocols, potentially impacting the reliability of the study’s results.

Who may qualify to participate in the Nektar class action?

Investors who purchased or acquired Nektar securities between February 26, 2025 and December 15, 2025 may be eligible if they suffered losses.

What is the deadline to seek lead plaintiff status in the Nektar lawsuit?

Investors seeking to serve as lead plaintiff must file a motion by May 5, 2026 to represent the shareholder class.

What does it mean when statements are “materially misleading”?

A statement is materially misleading if it omits or misrepresents facts that a reasonable investor would consider important when making an investment decision.

What does the term “class period” mean in a securities lawsuit?

The class period is the timeframe during which investors may have purchased the company’s securities while the alleged misleading statements were made.

What is a securities class action lawsuit?

A securities class action is a lawsuit filed on behalf of investors who claim they were harmed by false or misleading statements about a company.

What is a lead plaintiff in a securities class action?

The lead plaintiff is the investor appointed by the court to represent all shareholders in the class and work with attorneys during the litigation.

Do investors need to pay upfront to participate in a securities class action?

Most securities class actions are handled on a contingency basis, meaning legal fees are typically paid only if there is a recovery.

Nektar Therapeutics, Inc. - Faruqi & Faruqi LLP

Nektar Therapeutics, Inc.

Join Action

Case Details

Ticker NKTR

Class Period 02/26/2025 - 12/15/2025

Lead Plaintiff Deadline 05/05/2026

Days Left to Seek Plaintiff

If you are a Nektar Therapeutics investor who suffered a loss and would like to learn more, you can provide your information below:

If you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Nektar Therapeutics, Inc. (“Nektar” or the “Company”) (NASDAQ: NKTR) and reminds investors of the May 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) enrollment in the REZOLVE-AA trial had not followed applicable instructions and protocol standards; (2) the foregoing was likely to have a significant negative impact on the REZOLVE-AA trial’s results; (3) accordingly, the REZOLVE-AA trial’s overall integrity and prospects were overstated; and (4) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

Lead Plaintiff Deadline: May 5, 2026

Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310)
Or submit your information below to learn about your rights.

Join Action

Nektar Therapeutics, Inc.

Monetary Losses ($) *

Website URL

First Name *

Last Name *

Telephone *

Email *

Street Address

City

State

Zip Code

Purchases

1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Sales

1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Upload your trades here:

Accepted file types: xls, xlsx, doc, docx, pdf, jpg, jpeg, png, Max. file size: 50 MB, Max. files: 5.
You may redact account numbers from your uploaded documents.

File name:

File size:

Select File

Does not establish an attorney-client relationship *

By clicking this box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Faruqi & Faruqi LLP, and that the submission or receipt of information via this form, e-mail or telephone does not create an attorney-client relationship.

Case

Users to notify